Journal of Clinical Respiratory Diseases & Care: Open Access

Background: The vast majority of the ongoing antiviral/hostile to SARS-CoV-2 specialists are taken orally, and a little piece of the medication is arrived at the lung in light of unfortunate bioavailability or gastrointestinal deterioration. Consequently, breathed in treatment by pneumonic medication conveyance could be viewed as an expected game-plan to deal with pneumonic sicknesses like Coronavirus. Through pneumonic conveyance, it is feasible to convey medications to the lung straightforwardly which guarantees higher medication fixation in the lung and maintains a strategic distance from undesirable unfavorable impacts as lower dosages are required.